TrialInternational journal of cancer2025

Pirtobrutinib in Chinese patients with relapsed or refractory B-cell malignancies: A single-arm, open-label, phase 2, multicenter trial.

Yanyan Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.